Handelsavisen
prelaunch
Companies ›Healthcare ›RLAY.O
RL
RLAY.O — NASDAQ Biotechnology

Rlay.O

$18,72
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-1 971,6 %
ROE
-48,8 %
Net margin
-1 800,6 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$19,45
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Relay Therapeutics Inc operates in the biotechnology sector within the Health Care industry, though specific business activities and revenue generation mechanisms are not detailed in the available data.

Business. Relay Therapeutics Inc operates in the biotechnology sector within the Health Care industry, though specific business activities and revenue generation mechanisms are not detailed in the available data.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability→
-48,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning RLAY.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RLAY.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Relay Therapeutics Inc operates in the biotechnology sector within the Health Care industry, though specific business activities and revenue generation mechanisms are not detailed in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    (a) Capital structure and liquidity: The company maintains a debt-free balance sheet with a debt-to-equity ratio of 0.0. Total assets stand at $621.3 million, funded primarily by total equity of $567.1 million and total liabilities of $54.3 million. Cash and equivalents are reported at $84.0 million. Despite the strong equity base, operating cash flow is negative at -$235.5 million, indicating significant cash burn. The risk assessment flags liquidity as low, likely due to the negative cash flow trajectory relative to cash reserves.

    (b) Profitability and returns: The company is not profitable, reporting a net income of -$276.5 million and an operating income of -$302.7 million. Return on equity is -48.76% and return on assets is -44.5%, reflecting the substantial losses relative to the capital base. Revenue is minimal at $15.4 million, which is insufficient to cover operating expenses. No cohort median data is available to benchmark these metrics against industry peers.

    Key takeaways
    • The company is debt-free with $84.0 million in cash but faces low liquidity risk due to negative operating cash flow of -$235.5 million.
    • Significant losses are reported with a net income of -$276.5 million and minimal revenue of $15.4 million.
    • Return on equity is -48.76%, indicating substantial erosion of shareholder capital.
    • Dilution risk is assessed as low with no immediate flags detected.
    • Classification confidence is low (0.20), and specific business activities are not detailed.
    • No historical trend data or segment breakdowns are available for deeper analysis.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $18,72
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $567.1M
    Net cashⓘ
    $84.0M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -44.5%
    ROEⓘ
    -48.8%
    Cash conversionⓘ
    85.0%
    CapEx / revenueⓘ
    2.7%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution14 analysts
    Strong buy5
    Buy9
    Hold0
    Sell0
    Strong sell0
    12-month price target$25,92 · Median $26,50
    Low $20,00High $32,00
    Operating income · consensus-309,8M USD
    EPS surprise
    −3,9 %
    reported vs consensus · miss
    Revenue surprise
    +30,4 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$20,00
    Mean$25,92
    Median$26,50
    High$32,00
    Spot$18,72
    +38.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-1 971,6 %Bottom quartile
    Net Margin-1 800,6 %Bottom quartile
    ROE-48,8 %Below median
    Capex / Rev2,7 %Above median
    D/E0,00Above median
    Cash Conv0,85Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 3 281 789 sh5 exercises · 13 grants11 insiders
    • Catinazzo ThomasChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 56 323 @ $5,04exercise · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 61 563 @ $5,22exercise · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 51 560 @ $4,45exercise · 2026-06-22
    • Bergstrom Donald APresident, R&D · Stock Option (Right to Buy) → Common StockDisposed 93 456 @ $4,12exercise · 2026-06-22
    • Borisy AlexisDirector · Stock Option (Right to Buy) → Common StockAcquired 32 947 @ $14,09grant · 2026-06-09
    • COATS LONNELDirector · Stock Option (Right to Buy) → Common StockAcquired 32 947 @ $14,09grant · 2026-06-09
    • INGRAM DOUGLAS SDirector · Stock Option (Right to Buy) → Common StockAcquired 32 947 @ $14,09grant · 2026-06-09
    • Murcko MarkDirector · Stock Option (Right to Buy) → Common StockAcquired 32 947 @ $14,09grant · 2026-06-09
    • HILL LINDA ADirector · Stock Option (Right to Buy) → Common StockAcquired 32 947 @ $14,09grant · 2026-06-09
    • Dable Habib JDirector · Stock Option (Right to Buy) → Common StockAcquired 32 947 @ $14,09grant · 2026-06-09
    • Mazumdar ClaireDirector · Stock Option (Right to Buy) → Common StockAcquired 32 947 @ $14,09grant · 2026-06-09
    • Catinazzo ThomasChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 1 800 @ $5,22exercise · 2026-04-09
    • Bergstrom Donald APresident, R&D · Stock Option (Right to Buy) → Common StockAcquired 575 000 @ $7,94grant · 2026-01-13
    • Rahmer PeterSee remarks · Stock Option (Right to Buy) → Common StockAcquired 475 000 @ $7,94grant · 2026-01-13
    • Patel SanjivDirector, President and CEO · Stock Option (Right to Buy) → Common StockAcquired 1 450 000 @ $7,94grant · 2026-01-13
    • Catinazzo ThomasChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 400 000 @ $7,94grant · 2026-01-13
    • COATS LONNELDirector · Stock Option (Right to Buy) → Common StockAcquired 207 931 @ $6,86grant · 2025-11-04
    • Dable Habib JDirector · Stock Option (Right to Buy) → Common StockAcquired 207 931 @ $6,86grant · 2025-11-04

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Capex To Revenue
      capital_expenditure / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    Source documents
    • Relay Therapeutics, Inc. Market data — financials · 2026-08-01
    • reconciler_enqueue (reconciler) on RLAY.O · 2026-08-01

    Ownership & reference

    Top holders

    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$29M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,01 %$13M
    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$7M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$25M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$4M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$17M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$35M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$62M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$37M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$11M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$69M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$82M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$3M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$7M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$5M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$14M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$4M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$3M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$4M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Sanjiv K. PatelPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 26 sellsnet -$8,7M4 insiders · last 365d
    • Bergstrom Donald APresident, R&D · Common StockSold 2 237 @ $18,61$42K · 2026-07-28
    • Catinazzo ThomasChief Financial Officer · Common StockSold 1 459 @ $18,61$27K · 2026-07-28
    • Rahmer PeterSee remarks · Common StockSold 748 @ $18,61$14K · 2026-07-28
    • Patel SanjivDirector, President and CEO · Common StockSold 48 199 @ $19,58$944K · 2026-07-07
    • Catinazzo ThomasChief Financial Officer · Common StockSold 17 717 @ $18,69$331K · 2026-07-06
    • Bergstrom Donald APresident, R&D · Common StockSold 8 660 @ $18,71$162K · 2026-07-06
    • Patel SanjivDirector, President and CEO · Common StockOther 3 056 @ $6,95$21K · 2026-06-30
    • Rahmer PeterSee remarks · Common StockOther 3 056 @ $6,95$21K · 2026-06-30
    • Rahmer PeterSee remarks · Common StockSold 50 000 @ $19,09$954K · 2026-06-30
    • Catinazzo ThomasChief Financial Officer · Common StockSold 17 717 @ $17,01$301K · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Common StockOther 56 323 @ $5,04$284K · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Common StockSold 56 323 @ $16,97$956K · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Common StockOther 61 563 @ $5,22$321K · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Common StockSold 61 563 @ $16,97$1,0M · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Common StockOther 51 560 @ $4,45$229K · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Common StockSold 51 560 @ $16,97$875K · 2026-06-22
    • Bergstrom Donald APresident, R&D · Common StockOther 93 456 @ $4,12$385K · 2026-06-22
    • Bergstrom Donald APresident, R&D · Common StockSold 93 456 @ $16,94$1,6M · 2026-06-22
    • Catinazzo ThomasChief Financial Officer · Common StockSold 17 717 @ $12,86$228K · 2026-05-14
    • Rahmer PeterSee remarks · Common StockSold 753 @ $14,79$11K · 2026-04-28
    • Catinazzo ThomasChief Financial Officer · Common StockSold 972 @ $14,79$14K · 2026-04-28
    • Bergstrom Donald APresident, R&D · Common StockSold 1 490 @ $14,79$22K · 2026-04-28
    • Catinazzo ThomasChief Financial Officer · Common StockOther 1 800 @ $5,22$9K · 2026-04-09
    • Catinazzo ThomasChief Financial Officer · Common StockSold 1 800 @ $15,00$27K · 2026-04-09
    • Catinazzo ThomasChief Financial Officer · Common StockSold 17 717 @ $13,01$230K · 2026-04-07

    Short positioning

    42.6Mshares short-1.1% vs prior
    13.38days to cover
    44.4%short of daily vol
    182fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RLAY.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Revenue (annual): USD 15.36MUnknown
    • Total operating expenses (annual): USD 318.09MUnknown
    • Net income (annual): USD -276.48MUnknown
    • Shareholders' equity (annual): USD 567.06MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -2Unknown
    • Capex (annual): USD 410KUnknown
    • Shares outstanding (annual): 173.87MUnknown
    • Cash & equivalents (annual): USD 84.02MUnknown
    • Operating income (annual): USD -302.74MUnknown
    • Operating cash flow (annual): USD -235.46MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -2Unknown
    • Current assets (annual): USD 578.28MUnknown
    • Total assets (annual): USD 621.33MUnknown
    • Total liabilities (annual): USD 54.27MUnknown
    • Current liabilities (annual): USD 25.58MUnknown
    • Net income (annual): USD -337.71MUnknown
    • Revenue (annual): USD 10.01MUnknown
    • Capex (annual): USD 2.02MUnknown
    • Current liabilities (annual): USD 50.73MUnknown
    • Current assets (annual): USD 809.2MUnknown
    • Operating cash flow (annual): USD -249.11MUnknown
    • Operating income (annual): USD -372.47MUnknown
    • Shareholders' equity (annual): USD 777.79MUnknown
    • Total operating expenses (annual): USD 382.48MUnknown
    Showing 24 of 28 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-28INSIDERBergstrom Donald A sold 2.2k sh — President, R&D ~$42k
    2026-07-28INSIDERCatinazzo Thomas sold 1.5k sh — Chief Financial Officer ~$27k
    2026-07-28INSIDERRahmer Peter sold 748 sh — See remarks ~$14k
    2026-07-07INSIDERPatel Sanjiv sold 48.2k sh — Director, President and CEO ~$944k
    2026-07-06INSIDERCatinazzo Thomas sold 17.7k sh — Chief Financial Officer ~$331k
    2026-07-06INSIDERBergstrom Donald A sold 8.7k sh — President, R&D ~$162k
    2026-06-30INSIDERPatel Sanjiv transacted 3.1k sh — Director, President and CEO ~$21k
    2026-06-30INSIDERRahmer Peter transacted 3.1k sh — See remarks ~$21k
    2026-06-30INSIDERRahmer Peter sold 50.0k sh — See remarks ~$954k
    2026-06-22 00:00 UTCINSIDER20 insider transactions — 2026-06 · net sell $3.5M 11 derivative
    2026-06-22 00:00 UTCINSIDER20 insider transactions — 2026-06 · net sell $3.5M 11 derivative
    2026-06-22INSIDERCatinazzo Thomas sold 17.7k sh — Chief Financial Officer ~$301k
    2026-06-22INSIDERCatinazzo Thomas transacted 56.3k sh — Chief Financial Officer ~$284k
    2026-06-22INSIDERCatinazzo Thomas sold 56.3k sh — Chief Financial Officer ~$956k
    2026-06-22INSIDERCatinazzo Thomas transacted 61.6k sh — Chief Financial Officer ~$321k
    2026-06-22INSIDERCatinazzo Thomas sold 61.6k sh — Chief Financial Officer ~$1.04M
    2026-06-22INSIDERCatinazzo Thomas transacted 51.6k sh — Chief Financial Officer ~$229k
    2026-06-22INSIDERCatinazzo Thomas sold 51.6k sh — Chief Financial Officer ~$875k
    2026-06-22INSIDERBergstrom Donald A transacted 93.5k sh — President, R&D ~$385k
    2026-06-22INSIDERBergstrom Donald A sold 93.5k sh — President, R&D ~$1.58M
    2026-06-22INSIDERCatinazzo Thomas disposed of 61.6k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-22INSIDERBergstrom Donald A disposed of 93.5k sh Stock Option (Right to Buy) — President, R&D
    2026-06-22INSIDERCatinazzo Thomas disposed of 51.6k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-22INSIDERCatinazzo Thomas disposed of 56.3k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-09FILING8-K filing →
    2026-06-09INSIDERCOATS LONNEL acquired 32.9k sh Stock Option (Right to Buy) — Director
    2026-06-09INSIDERMurcko Mark acquired 32.9k sh Stock Option (Right to Buy) — Director
    2026-06-09INSIDERMazumdar Claire acquired 32.9k sh Stock Option (Right to Buy) — Director
    2026-06-09INSIDERDable Habib J acquired 32.9k sh Stock Option (Right to Buy) — Director
    2026-06-09INSIDERHILL LINDA A acquired 32.9k sh Stock Option (Right to Buy) — Director
    2026-06-09INSIDERBorisy Alexis acquired 32.9k sh Stock Option (Right to Buy) — Director
    2026-06-09INSIDERINGRAM DOUGLAS S acquired 32.9k sh Stock Option (Right to Buy) — Director
    2026-05-21FILING8-K filing →
    2026-05-21FILING424B5 filing →
    2026-05-19FILING424B5 filing →
    2026-05-19FILING8-K filing →
    2026-05-14 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $228k
    2026-05-14 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $228k
    2026-05-14INSIDERCatinazzo Thomas sold 17.7k sh — Chief Financial Officer ~$228k
    Showing the 40 most recent of 61 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage